Objective-Recent clinical evidence has failed to demonstrate the benefits of elevation of serum high-density lipoprotein (HDL), suggesting potential loss of protective effects of HDL at high concentrations. This study aimed to investigate the concentration-related effects of HDL on in vitro and in vivo functions of human endothelial progenitor cells (EPCs) and related angiogenesis. Methods and Results-Early and late outgrowth EPCs were generated from human circulating mononuclear cells. Oxidized low-density lipoprotein reduced viability of late outgrowth EPCs, which was reversed dose dependently by HDL. In the absence of oxidized low-density lipoprotein, HDL at low concentrations (5-50 μg/mL, equal to 0.5-5 mg/dL in human) enhanced EPC tube formation by activating phosphatidylinositol-3 kinase/Akt/endothelial NO synthase pathways. Moderate to high concentrations (400-800 μg/mL) of HDL paradoxically enhanced EPC senescence and impaired tube formation by activating Rho-associated kinase (ROCK) and inhibiting phosphatidylinositol-3 kinase/Akt and p38 mitogen-activated protein kinase pathways. Rho-associated kinase inhibitors, either Y27632 or statins, prevented high HDL-induced EPC senescence and improved in vitro tube formation, as well as in vivo capacity of angiogenesis of EPCs.
H igh-density lipoprotein (HDL) was previously suggested to protect against the progression of atherosclerosis because serum HDL levels could be reduced in patients with coronary artery disease (CAD), 1 and reduced HDL level might be an independent risk factor for cardiovascular diseases. 2, 3 These findings provide an epidemiological argument in favor of therapeutically raising HDL levels in patients with dyslipidemia. 4 However, recent clinical evidence raised the disagreement regarding whether HDL could independently exert a protective effect, especially in healthy subjects. [5] [6] [7] It has been shown that the ratio of serum total cholesterol to HDL level, rather than HDL level alone, is an independent predictor of future cardiovascular events both in healthy subjects 5 and in patients with stable CAD. 8 Furthermore, most of the interventions on serum HDL were performed in the context of marked changes in other plasma lipids, such as total cholesterol and low-density lipoprotein (LDL). 4 It was shown that low HDL level increased the cardiovascular risk in patients with high LDL level, but high HDL level did not necessarily decrease the risk in patients with relatively low LDL level (<70 mg/dL). 9 Besides, it was also indicated that HDL levels >75 mg/dL in healthy women and >55 mg/dL in healthy men did not provide additional beneficial effects. 2 Furthermore, recent large-scaled clinical trials focusing on elevation of serum HDL level by different pharmacological approaches did not provide additional clinical benefit, especially when the so-called harmful lipids, such as LDL and modified LDL, have been adequately reduced. [10] [11] [12] [13] Although the underlying mechanisms still await clarification, from an epidemiological standpoint, the current evidence does not support the solitary elevation of HDL level for clinical cardiovascular protection in the absence of other abnormal lipid profiles. 13 Further investigations are required to elucidate the potential mechanisms for loss of protective effects of high HDL level, especially when the so-called harmful lipids, such as LDL level, are normal or have been normalized.
Previous experimental studies have shown the various degrees of success with the treatment of reconstituted HDL in in vitro endothelial cells and in in vivo hindlimb ischemic or deendothelilization mouse models. [14] [15] [16] [17] Other in vitro studies also demonstrated that native HDL (in 20-100 μg/mL) can enhance the migration 18 and native HDL (in 10-50 μg/mL) may activate endothelial NO synthase (eNOS) in mature endothelial cells. 19 In most of these studies, HDL was given at relatively low concentrations (1-100 μg/mL, equal to 0.1-10 mg/dL or 0.0026-0.26 mmol/L in humans). The direct effects of HDL at normal to high physiological concentrations (300-800 μg/mL, equal to 30-80 mg/dL in human) remained unknown.
Recent clinical and experimental studies suggested that early endothelial progenitor cells (EPCs) could be a prognostic indicator of clinical atherosclerosis diseases, [20] [21] [22] [23] and late outgrowth EPCs may further contribute to vascular repair as well as angiogenesis upon tissue ischemia. [23] [24] [25] Investigations of the effects of native HDL on EPCs and its capacity of angiogenesis might provide additional insights into the physiological roles of HDL in vascular protection. It was shown that human plasma HDL levels were positively correlated with the number of early EPCs, and low concentration (50 μg/mL) of HDL upregulated early EPCs by activating eNOS and by preventing apoptosis. 26 However, it was also shown that in vitro incubation of mononuclear cells with native HDL at concentrations >30 μg/mL did not increase the number of EPCs, suggesting the potential loss of beneficial effects with increasing HDL level, which is similar to some clinical observations. 27 Thus, to test the hypothesis that HDL may have concentration-related biphasic vascular effect, this study was conducted to investigate the direct effects of HDL at both low (5-100 μg/mL, equal to 0.5-10 mg/dL in human) and normal to high physiological concentrations (300-800 μg/mL, equal to 30-80 mg/dL in human) on the in vitro and in vivo angiogenesis capacity of early and late EPCs. The potential molecular mechanisms related to the biphasic effects of HDL were also studied.
Materials and Methods

In Vitro Study
Reagents and Antibodies
Please see the online-only Data Supplement.
Preparation of Oxidized LDL and High-Density Lipoprotein
The LDL and HDL fraction of human serum was isolated and characterized, as previously described. 28, 29 The detailed protocol is given in the online-only Data Supplement.
EPC Isolation and Cultivation
EPCs were isolated from peripheral blood from healthy young male volunteers. The detailed protocol is given in the online-only Data Supplement.
EPC Characterization
The late EPC-derived outgrowth endothelial cells population was also characterized, and the detailed protocol is given in the onlineonly Data Supplement.
Measurement of Cytotoxicity by MTT Assay
The cytotoxicity of oxidized LDL (oxLDL) and HDL was analyzed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The detailed protocol is given in the online-only Data Supplement.
EPC Senescence Assay
Cellular aging was determined with a Senescent Cells Staining Kit (Sigma-Aldrich, CA). The detailed protocol is given in the onlineonly Data Supplement.
EPCs Tube Formation Assay
The tube formation assay was performed on EPCs to assess angiogenesis capacity, which is believed to be important for new vessel formation. The detailed protocol is given in the online-only Data Supplement.
Western Blot Analysis
Western blot analysis was performed to identify the protein expression in EPCs. The detailed protocol is given in the online-only Data Supplement.
Pull-Down Assay for Detection of Rho Activity
The activation of Rho protein was analyzed using the Rho Activation Assay Kit (Catalog 17-294, Millipore, MA). The detailed protocol is given in the online-only Data Supplement.
Manufacture of Neoangiogenesis Gel
The manufacture of the neoangiogenesis gel was modified from a previous study. 30 The detailed protocol is given in the online-only Data Supplement.
In Vivo Study
Preparation of Animals and Study Protocol
All animals were treated according to protocols approved by the Institutional Animal Care Committee of the Taipei Medical University (Taiwan). The detailed protocol is given in the online-only Data Supplement.
Statistical Analyses
Values are expressed as mean±SEM. Statistical evaluation was performed using the Student t test and 1-or 2-way ANOVA followed by Dunnett test. A probability value of P<0.05 was considered to be significant.
Results
Impaired Viability of EPCs Induced by oxLDL Could be Prevented by HDL
The MTT assay was performed to analyze the cell viability and cytotoxicity of oxLDL. Treatment of EPCs with 25, 50, and 100 μg/mL of oxLDL for 12 hours reduced cell viability, as well as increased cell cytotoxicity, in a dose-dependent manner ( Figure  1A ). In contrast, pretreatment with 100, 400, and 800 μg/mL of HDL for 1 hour dose dependently prevented the reduction of cell viability induced by 100 μg/mL of oxLDL. Different from the protective effects of 800 μg/mL of HDL, pretreatment with 16 mmol/L mannitol, serving as an osmotic control, had no effect on cell viability. Besides, to monitor the number of cells that were dead and had been cleaved, we performed lactate dehydrogenase measurements in the culture medium when EPCs were treated by different concentrations of native HDL (25-800 μg/mL).
The results showed that lactate dehydrogenase levels did not rise significantly either with high HDL (400-800 μg/mL) or with low HDL (25-100 μg/mL) ( Figure I in the online-only Data Supplement). Taken together, our findings indicated that high HDL may enhance EPC senescence, which means stopping the replication process of EPC and reducing cell number as that shown in MTT assay but not causing cell death as that seen on lactate dehydrogenase levels.
Because the interactions between different lipoproteins could be complex in natural condition, we also did some additional tests to cotreat HDL in various concentrations (5-100 μg/mL) with oxLDL (5-50 μg/mL) in various concentrations on EPCs. The results showed that when EPCs were treated with low oxLDL, the phosphorylation of eNOS and the ability of tube formation induced by various concentrations of HDL are similar no matter with or without the presence of oxLDL. However, in the presence of high oxLDL, high HDL did not impair EPC eNOS activation and, on the contrary, could further enhance the activation of eNOS on EPCs ( Figure IIA and IIB in the online-only Data Supplement).
Solitary Presence of High Concentrations of HDL Increases Senescence and Impairs Tube Formation of EPCs
Treatment of EPCs with 5 to 100 μg/mL of HDL for 12 hours did not result in cell viability changes or cell cytotoxicity ( Figure 1B) . In contrast, treatment with 400 and 800 μg/mL of HDL significantly reduced cell viability (60.25±8.13% and 63.85±7.58% of control, respectively). To determine the onset of cellular aging, acidic β-galactosidase was detected as a biochemical marker of acidification, which is typical of EPC senescence. 31 To determine the time-dependent effects of HDL on senescence, EPCs were treated with 400 μg/mL of HDL for 0.5 to 4 hours. It was shown that senescence may Figure 1 . The effects of oxidized low-density lipoprotein (oxLDL) and high-density lipoprotein (HDL) on cell cytotoxicity, senescence, and tube formation. A, After treatment of endothelial progenitor cells (EPCs) with 25 to 100 μg/mL of oxLDL for 12 hours and pretreatment with 100 to 800 μg/mL of HDL for 1 hour before treatment of oxLDL, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed, and the absorbance was recorded using a microplate reader. B, After the treatment of EPCs with 5 to 800 μg/mL of HDL for 12 hours, the MTT assay was performed. C, Acidic β-galactosidase was detected as a biochemical marker for acidification that is typical of EPC senescence. The treatment with 16 mmol/L mannitol served as osmotic control. The diagram shows the quantification of senescent EPCs. D, An in vitro angiogenesis assay was used with the ECMatrix gel to investigate the effect of HDL on EPC neovascularization. Representative photos of in vitro angiogenesis are shown. Data are expressed as the mean±SEM of 9 experiments performed in triplicate. *P<0.05 was considered significant. start early after 4 to 8 hours of HDL treatment ( Figure III in the online-only Data Supplement). However, compared with control medium, incubation of EPCs with >100 μg/mL HDL for 12 hours significantly enhanced the percentage of senescence-associated β-galactosidase-positive EPCs ( Figure 1C ). The finding indicates that EPC senescence could be enhanced by high concentrations of HDL but not low concentrations of HDL. To explore the potential effects of HDL on EPC angiogenesis, a tube formation assay was performed. It has been shown that EPCs successfully initiate capillary network formation on Matrigel. 24 After 12 hours of culture in 25 μg/mL HDL, the functional capacity for tube formation of EPCs on ECMatrix gel was significantly increased compared with the control group (160.33±15.19% of control). Interestingly, treatment of EPCs with HDL at 400 or 800 μg/mL for 12 hours significantly decreased cell tube formation (70.6±9.3% or 63.8±6.5% of control, respectively) compared with the control group. However, administration of mannitol (16 mmole/L for osmotic control) did not alter the EPC tube formation ( Figure  1D ). The results indicate that low concentrations (25-50 μg/mL) of HDL potentially increased the EPC capacity for tube formation, whereas higher concentrations (400 and 800 μg/mL) of HDL induced cell cytotoxicity and senescence and impaired tube formation of EPCs. Furthermore, these effects may be independent of the osmotic changes.
Besides, to evaluate whether the above effects of the native HDL from healthy donors could also be seen in HDL from different types of donors, we isolated the native HDL from 4 patients with CAD documented by coronary angiography and free from 3-hydroxyl-3-methyl coenzyme A reductase inhibitors (statins). It is shown that the effects of native HDL obtained from patients with CAD could be similar to that of native HDL obtained from healthy donors on tube formation and senescence of EPCs ( Figure IVA and IVB in the onlineonly Data Supplement). However, in low concentration, the native HDL obtained from healthy donors could activate eNOS of EPCs but the native HDL obtained from patients with CAD could not. However, at high concentration, both the native HDL obtained from healthy donors and that from patients with CAD could reduce the activation of eNOS in EPCs ( Figure  IVC in the online-only Data Supplement). These findings suggest the loss of beneficial effects of low concentration of native HDL obtained from patients with CAD on the activation of eNOS in EPCs. However, both high concentrations of native HDL obtained from healthy donors and that from patients with CAD may have similar harmful effects on EPCs.
In this study, a fraction of HDL (1.063-1.210g/mL) that includes both HDL2 and HDL3 was used. To evaluate the individual effects of HDL2 and HDL3 on EPCs, we have purified HDL2 (>1.063 and <1.120 g/mL) and HDL3 (>1.120 and <210 g/mL) from healthy donors, according to the method previously described, 32 and treated them on EPCs in various doses (50-800 μg/mL). It was shown that tube formation and senescence of EPCs were similar when treated with HDL2, HDL3, or total native HDL ( Figure VA and VB in the onlineonly Data Supplement). Although HDL2 and HDL3 may have different effects on cholesterol transport, it seems that they have similar effects on tube formation and senescence of human EPCs.
Finally, given that the presence of endotoxin could affect EPC function, we quantified the levels of endotoxin by a chromogenic assay in the culture medium and in different HDL preparations by using Pierce LAL Chromogenic Endotoxin Quantification Kit (Thermo Scientific Co, PO). It was shown that in comparison with endothelin-free water (Thermo Scientific Co, PO) as the standard reference, there was no endotoxin detected either in the culture medium or in different HDL preparations ( Table I in 
PI3K /Akt, NO, p38 MAPK, and JNK-/SAPK-Related Pathways Contribute to EPC Tube Formation
We have previously shown that phosphatidylinositol-3 kinase (PI3K)/Akt-, NO-, and p38 mitogen-activated protein kinase (MAPK)-related mechanisms could be involved in the angiogenesis capacity of high glucose-stimulated EPCs. 21 Therefore, in this study, we investigated whether PI3K/Akt, NO, and MAPK regulate tube formation in native and HDLtreated EPCs. After 1 hour of incubation with LY294002 (a PI3K inhibitor), SP600125 (a c-Jun N-terminal kinases [JNK]/stress− activated protein kinase [SAPK inhibitor]), SB203580 (p38 MAPK inhibitor), or L-N g -nitro-L-arginine methyl ester (L-NAME, an NO synthase inhibitor), tube formation was significantly decreased in native EPCs. Treatment with S-nitrosothiol (an NO donor) significantly increased tube formation in EPCs. In contrast, treatment with PD98059, an mitogen-activated protein kinase kinase 1 antagonist, did not decrease tube formation of EPCs, suggesting that the extracellular regulated protein kinases 1 and 2 signaling pathways might not participate in tube formation of naive EPCs (Figure 2A ). Treatment with SB203580 or SP600125 but not PD98059 significantly inhibited endogenous activation of eNOS ( Figure 2B ). Incubation with high concentrations (100, 400, or 800 μg/mL) of HDL significantly decreased eNOS phosphorylation at Ser 1177 in EPCs ( Figure 2C ). However, treatment with relatively low concentration (25 μg/mL) of HDL activated the phosphorylation of Akt and eNOS in EPCs, which could be inhibited by pretreatment with LY294002 ( Figure 2C and 2D). Besides, treatment with low concentration (25 μg/mL) of HDL did not alter the activation of p38 MAPK and JNK/ SAPK, the significant pathways for tube formation of native EPCs (Figure 2E ). To determine whether PI3K/Akt-related eNOS activation could contribute to the effects of low concentrations of HDL on tube formation of EPCs, cells were pretreated with S-nitrosothiol, L-NAME, or LY294002. EPC tube formation was significantly increased by 25 μg/mL of HDL, which could be inhibited by pretreatment with L-NAME or LY294002. However, EPC tube formation was not increased by 100 μg/mL of HDL. Similar to that in 25 μg/mL of HDL, pretreatment with L-NAME or LY294002 decreased the tube formation of EPCs in the presence of 100 μg/mL of HDL. However, S-nitrosothiol treatment increased EPC tube formation in the presence of 100 μg/mL of HDL ( Figure 2F ). These data indicate that the PI3K/Akt-, NO-, p38 MAPK-, and JNK/SAPK-related pathways may contribute to tube formation of EPCs. Low concentration (25 μg/mL) of HDL could enhance EPC tube formation by activating PI3K/Akt-and eNOS-related mechanisms. However, increased concentration (100 μg/mL) of HDL failed to increase EPC tube formation probably attributable to insufficient eNOS Figure 2 . The phosphatidylinositol-3 kinase/Akt-, NO-, p38 mitogen-associated protein kinase-, and stress-activated protein kinase (JNK)/stress-activated protein kinase (SAPK)-related pathways may contribute to endothelial progenitor cell (EPC) tube formation. A, EPCs were pretreated with 5 μmol/L LY294002 (LY), 10 μmol/L SP600125 (SP), PD98059 (PD), SB203580 (SB), S-nitrosothiol (SNAP), or L-NAME (LN) for 1 hour before the tube formation assay, which was performed for 6 hours. Representative photos depicting in vitro angiogenesis are shown. B, EPCs were pretreated with 10 μmol/L SP, PD, or SB for 4 hours before Western blot analysis. C, EPCs were treated for 2 hours with 25 to 800 μg/mL high-density lipoprotein (HDL), and endothelial NO synthase (eNOS) activation (phosphorylation) was analyzed by Western blotting. D, EPCs were pretreated for 1 hour with LY followed by treatment with 25 μg/mL HDL for 2 hours. The eNOS and Akt activation were analyzed by Western blotting. The total eNOS and total Akt protein levels were used as loading controls. activation because single nucleotide polymorphism supplement could still enhance EPC tube formation in such condition.
Rho Activation Is Critical to High HDL-Induced EPC Senescence
Previous evidence suggested that Rho GTPases (Rac1, Cdc42, and Rho A/B/C) are highly activated in senescent cells. 33 Thus, in this study, we investigated whether high concentrations (400 or 800 μg/mL) of HDL could induce EPC senescence and impair EPC function via Rho GTPases activation. The Clostridium difficile toxin B-10463 (TcdB-10463, a RhoA/ Rac1/Cdc42 inhibitor), GGTI-286 (a specific inhibitor of geranylgeranyltransferase-I and Rac/Cdc42), and Y27632 (a Rhoassociated kinase [ROCK] inhibitor) were used in this set of study. Pretreatment with TcdB-10463 or Y27632, but not with GGTI-286, for 1 hour significantly prevented EPC senescence ( Figure 3A ) and recovered the impairment of EPC tube formation induced by 400 μg/mL of HDL ( Figure 3B) . Thus, the activation of Rho A/B/C rather than Rac1 or Cdc42 might contribute to the adverse effects of high concentration of HDL on EPCs. Indeed, by using the Rhotekin-Rho fusion protein pull-down assay to detect Rho protein activity, we also demonstrated that HDL could activate Rho A/B/C in a dose-dependent and timedependent manner ( Figure 3C ). Given that high concentrations of HDL may decrease eNOS expression in EPCs, we sought to investigate whether this effect is mediated by Rho. Pretreatment of EPCs with 10 μmol/L Y27632 for 1 hour reversed the downregulation of eNOS activation by 400 or 800 μg/mL of HDL ( Figure 3D ). These results suggest that high concentrations of HDL may induce cell senescence and decrease tube formation of EPCs by activating Rho A/B/C protein.
HDL at High Concentrations Inhibit Endogenous p38 MAPK Activation
Western blotting analysis was done to assess the activation of other related signal pathways in EPCs treated with high concentrations of HDL. Although intracellular JNK/SAPK activation was not altered ( Figure 4A ), p38 MAPK activation was significantly and quickly inhibited by treatment of 400 μg/mL of HDL ( Figure 4B ), suggesting the potential role of p38 MAPK signal pathways in high concentrations of HDLinduced EPC dysfunction. Figure 3 . Rho A/B/C-related pathways may contribute to endothelial progenitor cell (EPC) tube formation. A, EPCs were pretreated with TcdB-10463, GGTI-286, or Y27632 for 1 hour followed by treatment with 400 μg/mL high-density lipoprotein (HDL) for 12 hours. Acidic β-galactosidase was detected as a biochemical marker for acidification, which is typical of EPC senescence. The diagram shows the quantification of senescent EPCs. B, EPCs were pretreated with TcdB-10463, GGTI-286, or Y27632 for 1 hour followed by treatment with 400 μg/mL HDL for 12 hours. An in vitro angiogenesis assay was performed to detect EPC neovascularization. Representative photos depicting in vitro angiogenesis are shown. Data are expressed as the mean±SEM of 3 experiments performed in triplicate. *P<0.05 was considered significant. C, After treatment of EPCs with 25 to 800 μg/mL of HDL for 45 minutes and with 400 μg/mL of HDL for 5 to 60 minutes, Rho A/B/C activation was analyzed using pulldown assays. The total Rho protein was used as a loading control. D, EPCs were pretreated for 1 hour with Y27632 followed by HDL treatment for 2 hours. Endothelial NO synthase (eNOS) activation was analyzed by Western blotting. The total eNOS protein was used as a loading control. Data are expressed as the mean±SEM of 9 experiments performed in triplicate. *P<0.05 was considered significant. October 2012
HDL at High Concentrations Inhibit Endogenous Akt and p38 MAPK via Rho Activation
Another series of Western blot analysis was done to investigate whether a high concentration of HDL may induce the activation of Rho protein and, consequently, inhibit the activation of endogenous Akt and p38 MAPK. Both 400 and 800 μg/mL of HDL significantly inhibited the intracellular Akt and p38 MAPK phosphorylation, which could be restored by pretreatment with 10 μmol/L of Y27632 ( Figure 4C and 4D) . These results suggest that high concentrations of HDL may inhibit endogenous Akt and p38 MAPK via Rho activation.
Statins Decrease Cell Senescence and Improve Impaired Tube Formation of EPCs
3-Hydroxyl-3-methyl coenzyme A reductase inhibitors, known as statins, are effective in lowering the plasma LDL concentration 34 and increasing the plasma HDL level. In addition, statins may exert a lipid-independent cardiovascular protective function via Rho kinase inhibition. 35 Therefore, EPCs were treated with rosuvastatin or atrovastatin for 30 minutes before treatment with 400 μg/mL of HDL. The results showed that rosuvastatin and atorvastatin effectively inhibited cell senescence ( Figure 5A ) and increased the capacity for tube formation ( Figure 5B ) in EPCs treated with a high level of HDL. In addition, the results of Western blot analysis and pull-down assays also demonstrated that rosuvastatin and atorvastatin increased eNOS activation and inhibited Rho A/B/C activation in EPCs treated with 400 μg/mL of HDL ( Figure 5C and 5D ).
Biphasic Effect of HDL on In Vivo Neoangiogenesis of Late Outgrowth EPCs
To investigate the in vivo effects of HDL on neoangiogenesis, the EPC/neoangiogenesis gel constructs were implanted into nonobese diabetic severe combined immunodeficiency mice. The constructs were harvested 21 days after implantation and embedded in optical coherence tomography (frozen tissue matrix). The frozen sections were assessed by immunohistochemical staining of CD31. The results are presented in Figure 6 . Consistent with the in vitro results, the vessellike structures were significantly more visible in the EPC/ neoangiogenesis gel containing 25 μg/mL of HDL than in the control group. However, the vessel-like structures were significantly decreased in EPC/neoangiogenesis gels containing 400 μg/mL of HDL than in control group and the group containing 25 μg/mL of HDL. However, adding Y27632 to the gel containing 400 μg/mL of HDL improved the formation of vessel-like structures. To determine whether the majority of tube structures were composed of human EPCs, a mock gel that contained no EPCs was also implanted for control. There was less staining with the antihuman CD31 antibody and no detectable vascular profiles, suggesting that the vessel-like structures were not formed by mouse cells (data not shown). Rosuvastatin and atorvastatin may effectively inhibit cell senescence and increase the capacity of tube formation. A, Endothelial progenitor cells (EPCs) were pretreated with rosuvastatin or atorvastatin for 30 minutes followed by 400 μg/mL high-density lipoprotein (HDL) for 12 hours. Cell senescence was analyzed. The diagram shows the quantification of senescent EPCs. B, EPCs were pretreated with rosuvastatin or atorvastatin for 30 minutes followed by 400 μg/mL HDL treatment for 12 hours. The tube formation capacity was analyzed. The diagram shows the quantification of tube formation. Data are expressed as the mean±SEM of 3 experiments performed in triplicate. *P<0.05 was considered significant. C, EPCs were pretreated with rosuvastatin or atrovastatin for 30 minutes followed by 400 μg/mL HDL treatment for 2 hours. eNOS activation was analyzed by Western blotting. D, EPCs were pretreated with rosuvastatin or atorvastatin for 30 minutes followed by 400 μg/mL HDL treatment for 45 minutes. Rho A/B/C activation was analyzed using pull-down assays. The total eNOS and total Rho protein levels were used as loading controls. Data are expressed as the mean±SEM of 9 experiments performed in triplicate. *P<0.05 was considered significant.
Discussion
The cardinal findings of this study indicate the differential effects of HDL on EPCs in the presence and absence of oxLDL, the concentration-related biphasic effects of native HDL on EPC function, and the beneficial effects of ROCK inhibitor and statins on the adverse effects of high concentrations of HDL on EPCs. First, oxLDL was shown to dose dependently reduce the cell viability of late outgrowth EPCs derived from healthy human peripheral blood. Although HDL protected EPCs from the injury of oxLDL in a dose-dependent fashion (100-800 μg/mL, equal to 10-80 mg/dL in human), the solitary presence of HDL did not increase, and even paradoxically impaired, the viability of EPCs at high concentrations (400-800 μg/mL, equal to 40-80 mg/dL in humans). These effects were osmotic independent. Thus, the direct protective effects of HDL could be mainly with the presence of oxLDL. Second, there were concentration-related biphasic effects of HDL on EPC function and related angiogenesis in the absence of oxLDL. Although low concentrations (10-50 μg/mL, equal to 1-5 mg/dL in human) of native HDL enhanced tube formation of EPCs by activating PI3K/Akt/eNOS pathways, moderate to high concentrations (400-800 μg/mL, equal to 40-80 mg/dL in human) of HDL enhanced cell senescence and impaired EPC function mainly by activating the ROCK pathways. The activation of ROCK pathways could inhibit PI3K/Akt phosphorylation and p38 MAPK pathways, resulting in reduced eNOS activation. Given the potential role of EPCs in vascular protection, our findings may provide the first mechanistic rationale to loss of protective effects of increasing serum HDL levels, especially when other lipid profiles are normal or have been normalized.
Biphasic Effects of HDL on Late Outgrowth EPCs in the Absence of oxLDL
In the present study, the concentration-dependent cell protective effects of native HDL could not be shown without the presence of oxLDL. While improving EPC survival in the presence of oxLDL, moderate to high concentrations of HDL paradoxically reduced cell viability and impaired EPC function in the absence of oxLDL. Thus, the direct beneficial effects of HDL on EPCs might be conditional. These findings are partially compatible with some clinical observations that there may be no additional benefits and even with potential hazards with significant elevation of serum HDL level especially when other lipid profiles, such as LDL, are relatively normal or have been normalized. [11] [12] [13] 36 It has been previously shown that low concentrations (10-50 μg/mL) of native HDL may regulate early EPCs 26 and mature endothelial cells 19, 32, [37] [38] [39] by increasing eNOS and preventing apoptosis. In mature endothelial cells, native HDL at low physiological concentrations (10-20 μg/mL) could interact with the scavenger receptor class B type I receptors to activate Src, PI3K, Akt kinase and MAPK pathways, resulting in eNOS activation. 19, 32, 37, 38 The scavenger receptor class B type I receptors could be also seen in our late outgrowth EPCs (data not shown). One may then speculate that HDL may activate EPCs via the mechanisms similar to that in mature endothelial cells. In fact, the current study did demonstrate that native HDL at low concentrations (10-50 μg/mL, equal to 1-5 mg/dL in human) could enhance late outgrowth EPC function via the activation of PI3K/Akt/ eNOS pathways. However, although the concentration of HDL was ≥100 μg/mL (400-800 μg/mL, equal to 40-80 mg/dL in human), the activation of eNOS could be paradoxically reduced in association with increased EPC senesceneses, and impaired cell viability and tube formation, which could be related to the action of ROCK pathways with consequent inhibition of eNOS phosphorylation.
In this study, the detailed mechanisms of the direct biphasic effects of HDL on EPCs were not completely elucidated. One of the possibilities is related to the effects of HDLassociated sphingosine-1-phosphate (S1P) on EPCs. Previous studies suggested that HDL-associated S1P may interact with the lysophospholipid receptors to activate eNOS via the AKT pathways 32, 40 and p42/44 MAPK pathways 41 and subsequently improve the migration, proliferation, and tube formation of endothelial cells. 16, [42] [43] [44] Reconstituted HDL containing S1P could also stimulate the differentiation of EPCs via PI3k/ Akt pathway and enhance ischemia-induced angiogenesis. 16 However, it was also suggested that HDL-associated S1P could exert bimodal regulation based on the diversity of S1P receptor isotypes, resulting in either stimulatory or inhibitory effects on cell migration. 45, 46 This hypothesis requires further investigation.
However, it would be interesting to know whether the biphasic effects of HDL from healthy subjects could also be seen with HDL from CAD patients. Our findings on EPCs are partially in agreement with the recent findings of Landmesser et al 47 in mature endothelial cells. They have demonstrated that because of reduced HDL-associated paraoxonase 1 activity, the native HDL (25-100 μg/mL) acquired from patients with CAD may not activate eNOS in mature endothelial cells and the subsequent loss of the endothelial anti-inflammatory and endothelial repair-stimulating effects of HDL. 32 In the current study, we treated EPCs with native HDL from CAD patients in concentrations from 25 μg/mL to 800 μg/mL. The patterns of EPC tube formation and senescence were similar in EPCs treated by HDL from CAD patients or by HDL from healthy volunteers. Interestingly, the HDL from CAD patients in low concentration could not activate eNOS in EPCs, whereas the HDL from healthy subjects could. However, both the high concentrations of HDL from CAD patients and that from healthy subjects paradoxically reduced the activation of eNOS in EPCs. Accordingly, HDL from CAD patients may be different from that from healthy donors in the activation of eNOS in EPCs, which is in concordance with that seen in mature endothelial cells. However, different from that in mature endothelial cells, both the HDL from CAD patients and that from healthy donors have similar effects on EPC tube formation and senescence. One of the possibilities is that the nature of EPCs may be different from that of mature endothelial cells. It has been suggested that EPCs may be more resistant to and could tolerate more oxidative stress than mature endothelial cells. [48] [49] [50] Though very interesting, these data are quite preliminary. Further work on this topic is ongoing to further delineate the underlying mechanisms.
High Concentrations of HDL Induce EPC Senescence by Activating ROCK Pathways
Previous evidences suggest that in addition to vascular endothelial cells, circulating EPCs could contribute to endothelial repair and angiogenesis. [48] [49] [50] There are at least 2 different kinds of socalled EPCs, including early and late outgrowth EPCs identified in recent years. 23 It has been indicated that late outgrowth rather than early EPCs could differentiate into mature endothelial cells [48] [49] [50] and have more direct contributions to neoagiogenesis. 23 Although they are very similar to mature endothelial cells in the gene expression profiles, late outgrowth EPCs have more rapid proliferation rate and less cell senescence, suggesting its nature of freshly differentiating young cells from adult stem cells. 23, 24 The topic of EPC senescence has gained attention in recent years. However, previous studies mainly focus on early rather than on late outgrowth EPCs. It has been shown that risk factors such as oxLDL, angiotensin II, and homocysteine could accelerate the senescence of early EPCs by increasing oxidative stress, which may be related to telomerase inactivation. [51] [52] [53] [54] Accordingly, in this study, we examined the possible role of NADPH oxidase-mediated reactive oxygen species production on high HDL-induced senescence of late outgrowth EPCs. The results showed that HDL at higher concentrations did not significantly increase reactive oxygen species production, and diphenylene iodonium (an NADPH oxidase inhibitor) cannot reverse the hazard effects of HDL on late outgrowth EPCs (data not shown). However, treatment with ROCK inhibitors effectively recovered Akt/eNOs activity and reversed the senescence of late outgrowth EPCs, suggesting the contribution of ROCK-mediated, eNOS-dependent pathways to high HDLinduced EPC senescence. The current findings are concordant with our previous findings that high glucose could induce the senescence of late outgrowth EPCs via an NO-dependent pathway, which is independent of oxidative stress. 29 The inhibition of the ROCK pathways by ROCK inhibitors including statins should provide a useful strategy to restore NO bioavailability and prevent senescence in late outgrowth EPCs. 55, 56 
High Concentrations of HDL Impair EPC Tube Formation by Activating ROCK Pathways
In this study, to simulate physiological endothelial repair and vascular regeneration, late outgrowth EPCs derived from healthy young subjects were used for in vitro tube formation and in vivo angiogenesis. The potential mechanisms by which HDL at high concentrations impaired EPC tube formation could be complex. Given that late outgrowth EPCs may have a greater potential for eNOS activation than early EPCs, NO-induced cell toxicity should be first considered for the adverse effects of high concentrations of HDL. However, it is not likely because treatment with higher concentrations of HDL reduced NO production in late outgrowth EPCs (data not shown). Furthermore, supplement of S-nitrosothiol, an NO donor, could reverse the impairment of EPC tube formation induced by high concentrations of HDL. However, ROCK inhibitors including statins could restore EPC tube formation, suggesting that HDL at high concentrations may impair EPC tube formation via the activation of ROCK.
It has been shown that small GTPases of the Rho family, primarily Rac, Cdc42, and Rho, may control cell motility through the regulation of actin organization and myosin motor function. 47, 57, 58 The ROCKs are downstream targets of the small GTP-binding protein Rho. [59] [60] [61] ROCKs may not only affect cell shape, motility, secretion, proliferation, gene expression, and apoptosis but also intersect with other signaling pathways known to contribute to cardiovascular disease by modulating vascular tone, proliferation, inflammation, and oxidative stress. 35, 62 It was suggested that the Rho activators, such as lysophosphatidic acid or S1P, may stimulate Rho guanine nucleotide exchange factor and lead to the formation of active GTP-bound Rho. 63 Although native HDL particles contain lysophospholipids including S1P, it is possible that HDL may also activate Rho and ROCKs by the S1P-related mechanisms.
Upon activation, the RhoA/ROCK-mediated actin cytoskeletal changes may induce the destabilization of eNOS mRNA. 64, 65 Binding of G-actin to the 3′-untranslated region of eNOS mRNA also decreases eNOS mRNA expression. 45 However, ROCK may also inhibit the phosphorylation of PI3K/protein kinase Akt and eNOS, 66, 67 resulting in the reduction of eNOS expression and activity. In this study, the activation of ROCK by high concentrations of HDL could reduce the phosphorylation of PI3K, Akt, and eNOS but not alter the stability of eNOS mRNA (data not shown). Besides, HDL at high concentrations inhibited the phosphorylation of p38 MAPK, which could be reversed by ROCK inhibitors. Taken together, moderate to high concentrations of HDL may activate ROCK-dependent PI3K-Akt pathways and p38 MAPK pathways probably by S1P-associated mechanisms, which may consequently induce EPC dysfunction. Further study may help to investigate whether modified HDL without S1P could avoid such biphasic effects.
Conclusions
Taken together, our findings showed the differential effects of native HDL on EPCs in the presence and absence of oxLDL, suggesting the conditional direct protective effects of HDL in the presence of oxLDL. In the absence of oxLDL, native HDL at low concentrations enhanced EPC tube formation by activating eNOS mechanisms, whereas HDL at normal to high physiological concentrations enhanced EPC senescence and impaired EPC function via the activation of ROCK pathways with consequent inhibition of eNOS activity. The potential hazards of high concentrations of HDL could be reversed by statins as the ROCK inhibitors. These findings may provide the first mechanistic evidence of concentration-related biphasic effects of HDL. Given the concept of dynamic vascular effects of HDL, future animal study and clinical investigation may be reqired to determine the proper serum HDL levels according to individual atherosclerosis risk profile.
